Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903122 · ClinicalTrials.gov registry record · Early Phase 1
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
A Early Phase 1 study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT01903122 is a Early Phase 1 study that has completed, run by Roxane Laboratories. The registered enrollment target is 26 participants.
The verdict
NCT01903122, a Early Phase 1 study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
Interventions
- DRUG Cevimeline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01903122
The ClinicalTrials.gov registry entry for NCT01903122 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cevimeline is the first listed.
NCT01903122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01903122 about?
NCT01903122 is a clinical study titled "Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
What is the current status of trial NCT01903122?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2009-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT01903122?
The interventions under investigation include: Cevimeline (DRUG).
Who is sponsoring clinical trial NCT01903122?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.